NCT02824822 Genetic Markers of Cardiovascular Disease in Epilepsy
| NCT ID | NCT02824822 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2016-05 |
| Primary Completion | 2031-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2016-05 with a primary completion date of 2031-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and sudden death related disorders in patients with epilepsy.
Eligibility Criteria
Inclusion Criteria: * Adults ages 18 - 50 with a diagnosis of epilepsy or seizures, or syncope or drowning or cardiac arrest or sudden death or an abnormal ECG suggestive of an arrhythmia * Blood-relatives (Aged 18+) of a patient with a history of epilepsy, seizure, cardiac arrest, sudden death, drowning, syncope or arrhythmia Exclusion Criteria: * Those who are unable to provide written consent. * Prisoners (vulnerable population) * Seizures secondary to ischemic events * Traumatic brain injury resulting in seizures * History of cranial surgery * History of brain tumor
Contact & Investigator
Somers CPL Lab
✉ CPL@mayo.eduVirend K. Somers, MD PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT02824822 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02824822 currently recruiting?
Yes, NCT02824822 is actively recruiting participants. Contact the research team at CPL@mayo.edu for enrollment information.
Where is the NCT02824822 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT02824822 clinical trial?
NCT02824822 is sponsored by Mayo Clinic. The principal investigator is Virend K. Somers, MD PhD at Mayo Clinic. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.